BioArctic Neuroscience and Eisai Extend Research Collaboration

BioArctic Neuroscience AB has signed an extension of an ongoing research collaboration on immunotherapy for Alzheimer’s disease with Eisai Co., Ltd., Japan.

The extension of the research agreement is a result of a strategic research alliance between BioArctic and Eisai initiated in 2005, to identify an effective treatment for Alzheimer’s disease. So far, this collaboration has delivered one antibody (BAN2401), which is in clinical development. BAN2401 is a novel humanized monoclonal antibody which targets the neurotoxin believed to cause Alzheimer’s disease.